United States

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

4:00pm EDT
Change (% chg)

$0.93 (+0.76%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for UTHR.OQ


United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH):... (more)


Beta: 1.57
Market Cap(Mil.): $5,481.25
Shares Outstanding(Mil.): 45.06
Dividend: --
Yield (%): --


  UTHR.OQ Industry Sector
P/E (TTM): 8.55 142.93 17.37
EPS (TTM): 14.22 -- --
ROI: 33.10 2.34 -5.89
ROE: 34.58 0.22 -5.30

BRIEF-United Therapeutics says it entered into first amendment to license agreement with Eli Lilly and company

* United Therapeutics Corp - on May 17, 2017, co entered into first amendment to license agreement with Eli Lilly and company

May 18 2017

BRIEF-United Therapeutics announces $250 mln share repurchase program

* United Therapeutics announces $250 million share repurchase program

Apr 27 2017

BRIEF-United Therapeutics and 3D Systems announce bioprinting agreement

* United therapeutics corp- 3d systems,united therapeutics today announced plans to develop solid-organ scaffolds for human transplants Source text for Eikon: Further company coverage:

Apr 26 2017

BRIEF-Respira Therapeutics says entered into strategic collaboration with United Therapeutics

* Respira Therapeutics says entered into a strategic collaboration with united therapeutics corporation for development and exclusive license of respira's rt234

Apr 12 2017

BRIEF-United Therapeutics announces regulatory delays for Remosynch Implantable Pump

* United Therapeutics-regulatory delays will result in postponement of planned U.S. launch of remosynch implantable system for remodulin until 2018

Apr 03 2017

BRIEF-United Therapeutics says Patent Trial and Appeal Board found that all claims of '393 patent are not patentable

* United Therapeutics announces decision from patent trial and appeal board and issuance of new patents

Mar 31 2017

BRIEF-United Therapeutics, Northwell Health's Feinstein Institute announce partnership

* United Therapeutics - co, Northwell Health's Feinstein Institute for Medical Research announced strategic partnership

Mar 09 2017

BRIEF-United Therapeutics reports Q4 non-GAAP eps of $4.12

* United Therapeutics Corporation reports 2016 fourth quarter and annual financial results

Feb 22 2017

More From Around the Web

Earnings vs. Estimates